Lan Peng, M.D. Professor School Medical School Department Pathology You have reached the Academic Profile. For more information on the doctor and patient care, please visit the clinical profile. Biography Lan Peng, MD, Professor of Pathology who is board-certified in anatomic pathology. Her clinical interests and expertise include pathology diagnosis for neoplastic and non-neoplastic liver, pancreas, and gastrointestinal pathology. Her research interests are acute liver failure, liver neoplasms, alcoholic and non-alcoholic liver diseases, colorectal and pancreatic cancer and underlying molecular mechanisms. Dr. Peng has served as co-investigator for about 10 research grants, including R01s, U01s, many other NIH/NCI grants as well as grants from various foundations. She has been actively involved in clinicopathologic studies on the histopathologic predictors and molecular biomarkers in pancreatic and GI and liver disorders. Her works were published in high-profile journals including Cell reports and Lancet Oncology. Education Medical School Hunan Medical College (1992) Residency New York University Hospital (2007), Pathology Fellowship UT MD Anderson Cancer Center (2008), Surgical Pathology Fellowship Mount Sinai Medical Center (2009), Liver & Gi Pathology Publications Featured Publications Nuclear localization of Argonaute 2 is affected by cell density and may relieve repression by microRNAs. Johnson KC, Kilikevicius A, Hofman C, Hu J, Liu Y, Aguilar S, Graswich J, Han Y, Wang T, Westcott JM, Brekken RA, Peng L, Karagkounis G, Corey DR, Nucleic Acids Res 2023 Dec A Rare Case of a Pancreatic Intraductal Oncocytic Papillary Neoplasm Associated With Invasive Adenocarcinoma Presenting as a Gastric Mass. Younes AI, Hu X, Peng L, Chi Z, Cureus 2023 Oct 15 10 e47886 Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma. Yin J, Elias R, Peng L, Levonyak N, Asokan A, Christie A, Kubiliun N, Brugarolas J, Hammers HJ, Clin Genitourin Cancer 2022 Feb GATA3 positivity is associated with poor prognosis in patients with oesophageal squamous cell carcinoma. Chi Z, Balani J, Gopal P, Hammer S, Xu J, Peng L, J Clin Pathol 2022 Jan Characterization of Desmoglein 3 (DSG3) as a Sensitive and Specific Marker for Esophageal Squamous Cell Carcinoma. Chi Z, Balani J, Gopal P, Hammer S, Lewis CM, Peng L, Gastroenterol Res Pract 2022 2022 2220940 Variations of P40 and P63 Immunostains in Different Grades of Esophageal Squamous Cell Carcinoma: A Potential Diagnostic Pitfall. Chi Z, Balani J, Gopal P, Peng L, Hammer S, Appl Immunohistochem Mol Morphol 2021 May Deep learning model for the prediction of microsatellite instability in colorectal cancer: a diagnostic study. Yamashita R, Long J, Longacre T, Peng L, Berry G, Martin B, Higgins J, Rubin DL, Shen J, Lancet Oncol 2021 01 22 1 132-141 Dietary simple sugars alter microbial ecology in the gut and promote colitis in mice. Khan S, Waliullah S, Godfrey V, Khan MAW, Ramachandran RA, Cantarel BL, Behrendt C, Peng L, Hooper LV, Zaki H, Sci Transl Med 2020 Oct 12 567 NLRP12 suppresses hepatocellular carcinoma via downregulation of cJun N-terminal kinase activation in the hepatocyte. Udden SN, Kwak YT, Godfrey V, Khan MAW, Khan S, Loof N, Peng L, Zhu H, Zaki H, Elife 2019 Apr 8 restrains pancreatic neoplasia formation. Wang SC, Nassour I, Xiao S, Zhang S, Luo X, Lee J, Li L, Sun X, Nguyen LH, Chuang JC, Peng L, Daigle S, Shen J, Zhu H Gut 2018 Oct Results 1-10 of 36 1 2 3 4 Next Last Books Featured Books Targeted gene repair in mammalian cells using chimerical Oligonucleotides.. In Genetic Engineering: Principles and Methods Kmiec EB, Ye S and Peng L (2001). New York, USA, Springer
